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Information regarding the most pertinent side effects were 
collected, as well as the perceived utility of the aid.  
Results: Thirty-two participants (16 men, 16 women) with a 
median age of 34.5 (range 18-64) enrolled in this study. Twenty-
six subjects (81%) selected TORS as their preferred treatment 
option. Tradeoff revealed that participants were willing to 
accept a median score of 10% (range 5-50) decrease in survival 
to maintain their treatment choice. Regarding side effect 
profiles, the most concerning risks of TORS were: bleeding, 
death, stroke and aspiration pneumonia. Whereas, the most 
concerning toxicities of RT were: tooth decay, need of a feeding 
tube, and the risk of secondary malignancy. Finally, all subjects 
indicated that if they would value having a similar tool available 
perchance they are in a similar situation. 
Conclusions: A novel web-based Decision Aid has been developed 
for patients with early oropharyngeal cancer. The finding that 
TORS was preferred over RT in a sample of healthy volunteers 
necessitates confirmation in a cohort of patients with early 
oropharyngeal cancer. This tool holds promise in the era of 
shared-decision making and personalized patient-centred care. 
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Purpose: The objectives of this study are to (1) quantify 
intrafraction motion (IFM) during lung volumetric-modulated arc 
therapy (VMAT) and (2) evaluate the impact of mid-treatment 
patient repositioning after cone beam computed tomography 
(CBCT) acquisition upon target coverage. 
Methods and Materials: This analysis included lung tumours 
treated with VMAT between April 2012 and June 2015 with 50-60 
Gy in 3-5 fractions. Treatment planning consisted of a four-
dimensional (4D) CT scan from which an internal target volume 
(ITV) delineation was performed. A 5 mm margin was added in 
all directions to obtain the final planning target volume (PTV). 
Treatment sessions were performed in supine position with a 
customized dual vacuum immobilization device (BodyFIX, Elekta, 
Stockholm, Sweden). All patients underwent pre and mid-
treatment CBCTs to ensure proper repositioning. Following each 
CBCT, a two-step rigid registration was performed by an 
experienced radiation oncologist according to the planning CT, 
taking into account organs at risk (OARs). Bone shift was first 
assessed with a registration of the vertebrae adjacent to the 
lesion. Then, tumour shift was isolated with a soft tissue 
registration by aligning targets. IFM, combining bone and tumour 
shifts, was defined as the target displacement from pre to mid-
treatment CBCT acquisition and was quantified in terms of 
anterior-posterior (AP), cranio-caudal (CC) and medio-lateral 
(ML) amplitudes as well as three-dimensional (3D) vector. For 
patients with IFM ≥ 5 mm, a post-hoc dose calculation analysis 
was performed to assess target coverage impacts of mid-
treatment CBCT-guided repositioning. 
Results: Ninety-seven patients, totalizing 367 fractions, were 
included. Mean (±SD) overall treatment time was 53:02 ± 13:08 
min. Mean time from pre to mid-treatment CBCT acquisition was 
22:58 ± 5:33 min. Mean time to perform mid treatment CBCT 
scan acquisition, registrations and couch repositioning was 15:49 
± 4:14 min. Mean IFM amplitudes were 0.9 ± 1.2 mm, 0.6 ± 1.0 
mm and 0.6 ± 0.8 mm in the AP, CC and ML respectively. IFM was 
< 3 mm and < 5 mm in all directions in respectively 315/367 (86%) 
and 358/367 (98%) fractions. Mean 3D IFM vector was 1.5 ± 1.4 
mm (max = 8.1 mm) and was < 5 mm in 354/367 (96%). Among 
the 13 fractions with IFM vector ≥ 5 mm, 11/13 (85%) were 
dominantly induced by a tumour shift. For all these fractions, 
dose calculation analysis of worst-case scenario indicates that 
ITV coverage would have remained ≥ 95% without mid-treatment 
CBCT-guided patient repositioning. 
Conclusions: For 96% of fractions in patients immobilized with a 
customized BodyFIX dual vacuum bag, the IFM vector was within 
the 5 mm PTV margin used. Mid-treatment CBCT-guided couch 
repositioning did not significantly impact ITV coverage and 
prolonged treatment duration. Mid-treatment imaging may 
remain pertinent for selected patients with strict OAR dose 
constraints. 
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Purpose: Chest wall (CW) pain is as a possible late toxicity after 
SBRT. Several dosimetric factors have been reported to predict 
it, however, with no clear validation. This article reports our 
institutional experience with CW pain and the search for dose 
constraints for the CW as organ at risk in a homogeneous group 
of patients treated with the same dose and fractionation, 
planned with heterogeneity correction, without any initial dose 
constraint to the CW at the initial planning. 
Material and Methods: Patients with localized lung tumours, 
treated with SBRT the way mentioned above, to a dose of 48 Gy 
in 3 fractions, with the PTV touching the CW were reviewed. CW 
(2 cm expansion) was contoured retrospectively. Using Eclipse 
(Varian) software, common metrics of the absolute volume of the 
CW receiving 30 Gy or more (V30Gy), the intersecting volumes 
(in cm3) between the PTV and CW volumes, the mean dose and 
the max dose of the CW volume were extracted. CW pain was 
graduated by Common Terminology Criteria for Adverse Events 
v3.0. Data analysis and data correlation was carried out using the 
widely used Dose Response Explorer System1 (DREES) software, 
which allows for analytical and data-driven outcome modeling. 
Results: Seventy-five lung lesions in 71 patients met the criteria 
for our study. After a median follow up of 16 months, five 
patients reported CW pain (3 Grade = 3 and 2 Grade = 2). Median 
time for CW pain to manifest was seven months. The median 
volume of CW receiving > 30 Gy was 26 cc (range: 0.1 – 126 cc). 
The V30 Gy volumes (cm3) of the five cases with CW pain were 
15, 15, 20, 47 and 100. For all lesions, mean Dose to CW = 54.2 
± 2.3 Gy. Median max CW dose = 57 Gy. After DREES analysis, no 
correlation between the variables studied and CW pain was 
found. 
Conclusions: CW pain is an important late toxicity after SBRT in 
lung tumours. V30 Gy of the CW has been often used to decrease 
the risk of CW pain, but the volume is not clear. None of the 
common variables (including V30 Gy) analyzed in this study was 
statistically significant for CW pain. Good dosimetric constraints 
to decrease risk of CW pain remain to be determined.  
(1) El Naqa I, et al. Dose response explorer: an integrated open-
source tool for exploring and modelling radiotherapy dose-
volume outcome relationships. Physics in Medicine and Biology 
2006. 
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Purpose: To assess the intra-fraction tumour stability of lung 
cancer patients treated by cone beam computed tomography-
guided (CBCT) stereotactic body radiotherapy (SBRT) without 
any frame or immobilization devices. 
Materials and Methods: Localized lung cancer patients were 
treated with SBRT, positioned supine, with arms held above the 
head, a foam support under the knees and without any further 
immobilization. Internal target volume (ITV) was generated from 
4D-CT simulation around which a 5 mm symmetric PTV margin 
was added. All patients (except one) received 48 Gy in 3 
